Quick Answer
Rani Therapeutics Holdings, Inc. reported Diluted EPS of $0.45 per share (loss) for fiscal year 2025.
Rani Therapeutics Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.45 | +57.1% |
| 2024 | -$1.05 | +21.1% |
| 2023 | -$1.33 | -3.9% |
| 2022 | -$1.28 | -197.7% |
| 2021 | -$0.43 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | +50.0% | +33.3% |
| June 30, 2025 | -$0.18 | +30.8% | +18.2% |
| March 31, 2025 | -$0.22 | +24.1% | +8.3% |
| September 30, 2024 | -$0.24 | +33.3% | +7.7% |
| June 30, 2024 | -$0.26 | +29.7% | +10.3% |
| March 31, 2024 | -$0.29 | +12.1% | +19.4% |
| September 30, 2023 | -$0.36 | -209.1% | +2.7% |
| June 30, 2023 | -$0.37 | -219.4% | -12.1% |
- Rani Therapeutics Holdings, Inc. showed an increase of +57.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Rani Therapeutics Holdings, Inc.’s diluted eps has declined by 4.7% (from $0.43 per share (loss) to $0.45 per share (loss)).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: